Company Overview and News

0
Panel blocks major shareholder

2018-04-26 businessnews.com.au
The Takeovers Panel has blocked a major shareholder of Finders Resources from accepting the recent takeover offer after the corporate watchdog submitted an application to the panel.
FND

0
Copper Mountain Mining now dual listed, gets ASX boost following Altona deal

2018-04-10 australianmining.com.au
Canadian company Copper Mountain Mining Corporation (CMMC) is now trading on the Australian Securities Exchange (ASX) following its $93 million acquisition of Altona Mining, first announced last November. The company already trades on the Toronto Stock Exchange (TSX).
OZMLF AOH CPPMF FND OZL

0
Finders in board overhaul

2018-04-04 businessnews.com.au
Finders Resources has announced a board overhaul following the recent $177 million takeover by Indonesian group Eastern Field Developments, with David Fowler appointed as acting chief executive.
FND

0
ASIC intervenes in Finders takeover

2018-03-29 businessnews.com.au
The corporate watchdog has submitted an application to the Takeovers Panel asking it to block certain shareholders of Finders Resources from accepting an offer for their shares.
FND

0
Eastern Field gains majority control of Finders Resources

2018-03-20 australianmining.com.au
Recently-established Indonesian copper consortium Eastern Field Developments has announced that its shareholding in Finders Resources is now over 50 per cent, making it the majority shareholder.
FND

0
Eastern Field takes control of Finders

2018-03-19 businessnews.com.au
Indonesian group Eastern Field has taken control of Finders Resources, five months after announcing its takeover deal, which values the copper miner at about $177 million.
FND

0
Panel throws out Eastern application

2018-03-13 businessnews.com.au
The Takeovers Panel has dismissed an application from Indonesian group Eastern Field Developments regarding its takeover target Finders Resources, with the panel determining that appropriate action has been taken by the company in relation to its Wetar project.
FND

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ASX:FND / FINDERS RESOURCES LIMITED on message board site Silicon Investor.

Fundtech [Nasdaq/ FNDT] (formerly FNDTF) vfnd
FND - INTERNET GROWTH FUND Fundtech Ltd. (FNDTF)